| Enanta Pharmaceuticals is a biotechnology company that creates small molecule drugs primarily for the treatment of viral infections and liver diseases. Co.'s wholly owned research and development programs are in virology, namely respiratory syncytial virus and hepatitis B virus, and in liver disease (non-virology), namely non-alcoholic steatohepatitis and primary biliary cholangitis. Through its Collaborative Development and License Agreement with AbbVie Inc (AbbVie), Co. has discovered and out-licensed to AbbVie two protease inhibitor compounds that have been clinically tested, manufactured, and commercialized by AbbVie for the treatment of hepatitis C virus. We show 31 historical shares outstanding datapoints in our ENTA shares outstanding history coverage, used to compute ENTA market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ENTA market cap history over the course of time is important for investors
interested in comparing ENTA's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ENTA versus a peer is one thing; comparing
ENTA market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ENTA can fluctuate over the course of history.
With this page we aim to empower investors researching ENTA by allowing them to research the ENTA market cap history.